AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reiterated by equities research analysts at Shore Capital in a report issued on Friday.

Other equities research analysts have also recently issued reports about the company. UBS AG set a GBX 5,150 ($66.86) price objective on AstraZeneca plc and gave the stock a “neutral” rating in a report on Thursday, April 27th. HSBC Holdings plc reiterated a “reduce” rating and issued a GBX 4,200 ($54.52) price objective on shares of AstraZeneca plc in a report on Friday, May 5th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of AstraZeneca plc in a report on Thursday, May 11th. Berenberg Bank lifted their price objective on AstraZeneca plc from GBX 5,670 ($73.61) to GBX 5,850 ($75.94) and gave the stock a “buy” rating in a report on Wednesday, May 17th. Finally, Liberum Capital reiterated a “buy” rating and issued a GBX 5,500 ($71.40) price objective on shares of AstraZeneca plc in a report on Tuesday, May 23rd. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of GBX 4,932.67 ($64.04).

AstraZeneca plc (LON AZN) opened at 4447.00 on Friday. The company’s market capitalization is GBX 56.30 billion. The company’s 50-day moving average price is GBX 4,818.59 and its 200-day moving average price is GBX 4,863.31. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.

TRADEMARK VIOLATION WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/shore-capital-reiterates-hold-rating-for-astrazeneca-plc-azn/1509412.html.

In other news, insider Nazneen Rahman bought 39 shares of the business’s stock in a transaction on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($56.73) per share, with a total value of £1,704.30 ($2,212.51).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.